📗 Cite This Artifact
C4A Gene
C4A Gene
Introduction
C4A Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">C4A Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>C4A</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Complement Component 4A (Chido/Rodgers Blood Group)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6p21.3 (MHC Class III)</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>712</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>120810</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000144711</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P0C0P0</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Complement system serine protease</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Schizophrenia, Systemic Lupus Erythematosus</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>High (increases with activation)</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Neurons</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">C1q</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">C1r</td>
<td>Protease cleavage</td>
</tr>
<tr>
<td class="label">C1s</td>
<td>Protease cleavage</td>
</tr>
<tr>
<td class="label">CR1 (CD35)</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">CR3 (CD11b/CD18)</td>
<td>Receptor binding</td>
</tr>
</table>
The C4A gene (Complement Component 4A) encodes a critical protein in the classical complement cascade, a key component of the innate immune system. Located in the major histocompatibility complex (MHC) class III region on chromosome 6p21.3, C4A plays essential roles in immune defense, synaptic pruning, and neuroinflammation["@sekar2016"]. Research over the past decade has revealed that C4A is critically involved in the pathogenesis of Alzheimer's disease, Parkinson's disease, schizophrenia, and other neurodegenerative conditions. The gene shows polymorphic variation in humans, including copy number variation (CNV) that has been associated with disease risk.
Gene Overview
Protein Structure and Function
Protein Architecture
C4A encodes the complement component 4A protein, a 1741-amino acid zymogen that undergoes proteolytic cleavage during activation. The protein consists of three polypeptide chains (α, β, and γ) held together by disulfide bonds:
- α-chain (104 kDa): Contains the thioester bond critical for covalent attachment to pathogen surfaces
- β-chain (75 kDa): Stabilizes the molecule in circulation
- γ-chain (28 kDa): C-terminal fragment
The thioester bond in the α-chain is a defining feature of C4, allowing it to covalently bind to hydroxyl groups on target surfaces through acylation[@zhou2020]. This distinguishes C4A from C4B, which preferentially binds amino groups.
Complement Pathway Functions
C4A participates in multiple complement activation pathways:
The cleavage products serve distinct functions:
- C4a: A potent anaphylatoxin that triggers histamine release, increases vascular permeability, and attracts immune cells
- C4b: An opsonin that covalently binds to pathogens and immune complexes, facilitating phagocytosis via complement receptors
Role in Neurodegeneration
Alzheimer's Disease
C4A has emerged as a significant factor in Alzheimer's disease pathogenesis through multiple mechanisms:
Neuroinflammation
Elevated C4A expression in the AD brain contributes to chronic neuroinflammation[@steckham2019]. Studies have shown that C4A levels are increased in AD brains compared to age-matched controls, particularly in regions affected by amyloid pathology. The complement protein is produced by activated microglia and astrocytes, creating a pro-inflammatory feedback loop that drives disease progression[@benoit2022].
Key mechanisms include:
- Microglial activation: C4A acts as a "find me" signal for microglia, promoting their recruitment to sites of pathology
- Cytokine production: C4A cleavage generates C4a, which triggers mast cell degranulation and cytokine release
- Blood-brain barrier permeability: C4a increases BBB permeability, allowing peripheral immune cells to enter the brain
Synaptic Pruning
The complement system plays a critical role in developmental synaptic pruning, and this mechanism is re-activated in Alzheimer's disease[@hong2016]. C4A contributes to:
- Synaptic tagging: C4b marks synapses for elimination by microglia
- Phagocytosis: Microglial complement receptors (CR3) recognize C4b-coated synapses
- Synaptic loss: Early synaptic loss in AD correlates with complement activation
Studies using mouse models have demonstrated that blocking complement components can prevent synapse loss, highlighting the therapeutic potential of targeting C4A[@veenvliet2020].
Amyloid Pathology
C4A interacts with amyloid-beta (Aβ) plaques in several ways:
- Plaque opsonization: C4b can bind to Aβ aggregates, marking them for microglial clearance
- Inflammatory amplification: Aβ activates microglia to produce more C4A, creating a feed-forward loop
- Alternative pathway activation: Aβ can activate the complement system independently of antibodies
Genetic studies have identified variants in the C4 region that modify AD risk, particularly in the MHC class III region that shows robust association in GWAS studies[@chen2019].
Parkinson's Disease
In Parkinson's disease, C4A contributes to dopaminergic neuron loss through:
Post-mortem studies have shown increased C4A expression in the substantia nigra of PD patients, particularly in proximity to Lewy bodies[@hawkes2023].
Schizophrenia
The strongest evidence linking C4A to disease comes from schizophrenia research:
C4A Copy Number Variation
Sekar et al. (2016) demonstrated that increased C4A copy number is associated with increased schizophrenia risk[@sekar2016]. The mechanism involves:
- Developmental synaptic pruning: Higher C4A expression during critical periods of brain development leads to excessive synapse elimination
- Synaptic density reductions: Post-mortem studies show reduced synaptic density in schizophrenia brains
- Genetic architecture: The C4 locus shows extensive variation that correlates with expression levels
Neurodevelopmental Hypothesis
The schizophrenia association supports a neurodevelopmental model where:
- Elevated C4A during adolescence/young adulthood prunes too many synapses
- This results in impaired neural connectivity
- Affected individuals develop psychosis in early adulthood
Multiple Sclerosis
C4A and C4B show opposing roles in multiple sclerosis[@van2020]:
- C4A appears protective in MS
- C4B may drive disease progression
- This dichotomy provides insights into complement-mediated neuroinflammation
Expression Pattern
Brain Expression
C4A is expressed in multiple cell types within the central nervous system:
Regional Distribution
C4A expression varies across brain regions:
- Hippocampus: High expression, particularly in CA1-3 regions
- Cortex: Moderate expression, layer-specific patterns
- Substantia nigra: Increased in PD
- Cerebellum: Lower expression
Age-Related Changes
C4A expression increases with age in the brain, which may contribute to age-related neurodegeneration. This age-related increase is amplified in AD and PD brains.
Genetic Variation
Copy Number Variation
The C4A gene shows extensive copy number variation:
- 1-5 copies per diploid genome
- Higher copy numbers → increased expression
- Copy number associated with schizophrenia and AD risk
Single Nucleotide Polymorphisms
GWAS studies have identified SNPs in the C4 region associated with:
- Alzheimer's disease risk
- Schizophrenia risk
- Systemic lupus erythematosus risk
- Multiple sclerosis progression
Therapeutic Implications
Complement Inhibition
Given the central role of C4A in neurodegeneration, complement inhibition represents a promising therapeutic strategy:
Challenges
- Host defense: Complement is essential for immune function
- Timing: Intervention may need to be early in disease course
- Specificity: Targeting C4A specifically while preserving C4B function
Research Directions
Current clinical trials are evaluating complement inhibitors in AD and other neurodegenerative conditions. The goal is to modulate neuroinflammation without compromising host defense[@presumey2022].
Protein Interactions
Clinical Significance
Diagnostic Biomarkers
C4A levels in cerebrospinal fluid (CSF) may serve as:
- Disease progression marker
- Therapeutic response indicator
- Prognostic biomarker
Genetic Testing
C4A CNV analysis may help identify:
- Individuals at risk for schizophrenia
- AD risk stratification
- Treatment response predictors
Research Methods
Experimental Models
- Mouse models: C4 knockout mice to study complement function
- In vitro models: Human microglia and neuron cultures
- iPSC models: Patient-derived cells for mechanistic studies
Key Research Techniques
- RNA-seq for gene expression analysis
- proteomics for protein level measurements
- GWAS for genetic association studies
- Immunohistochemistry for localization studies
Key Publications
Disease Associations
Top DisGeNET gene-disease associations for this gene are listed below. Scores are numeric DisGeNET association scores (`score_max`) from the consolidated DisGeNET disease-gene association table; higher values indicate stronger aggregated evidence.
| Disease | DisGeNET score | Evidence sources | Supporting PMID count |
|---|---:|---|---:|
| systemic lupus erythematosus | 0.243 | BeFree/CTD_human/GAD/LHGDN | 25 |
| psoriasis | 0.003 | BeFree/LHGDN | 3 |
| Graves' disease | 0.003 | BeFree/GAD | 2 |
| asthma | 0.003 | LHGDN | 1 |
| chronic obstructive pulmonary disease | 0.003 | LHGDN | 1 |
Source: DisGeNET-derived consolidated disease-gene associations (`dhimmel/disgenet`, gene symbol `C4A`).
See Also
- [Complement System](/entities/complement-system)
- [Microglia](/cell-types/microglia-neuroinflammation)
- [Astrocytes](/entities/astrocytes)
- [Synaptic Pruning](/mechanisms/synaptic-pruning)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Schizophrenia](/diseases/schizophrenia)
- [C4B Gene](/genes/c4b)
- [C1QA Gene](/genes/c1qa)
- [TREM2 Gene](/genes/trem2)
External Links
- [NCBI Gene: C4A](https://www.ncbi.nlm.nih.gov/gene/712)
- [UniProt: P0C0P0](https://www.uniprot.org/uniprot/P0C0P0)
- [OMIM: 120810](https://www.omim.org/entry/120810)
- [Ensembl: ENSG00000144711](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144711)
- [GWAS Catalog: C4A variants](https://www.ebi.ac.uk/gwas/)
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)
- [Allen Brain Atlas: C4A expression](https://human.brain-map.org/)
References
Benoit2022, Complement protein C1q-mediated neuroprotection is reversed by chronic systemic exposure to bacterial lipopolysaccharide (2022)
chen2019, Complement C4 gene expression in microglia: therapeutic implications for Alzheimer's disease (2019)
danielsen2022, Association between complement component C4 and neurodegenerative diseases (2022)
fischer2021, Complement C3/C3aR signaling in Alzheimer's disease: new therapeutic targets (2021)
gomez2020, Microglial dynamics in Alzheimer's disease (2020)
hawkes2023, Complement activation in Alzheimer's disease: therapeutic targeting (2023)
hong2016, Complement and microglia mediate synapse elimination during development (2016)
jackson2019, Complement component C4 and the risk of Alzheimer's disease: a systematic review and meta-analysis (2019)
lambert2013, Meta-analysis of the amyloid burden in cognitively normal individuals with autosomal dominant Alzheimer's disease (2013)
lintvedt2013, C4B deficiency is associated with increased risk of Alzheimer's disease (2013) [1](https://doi.org/10.3233/JAD-121714)
morris2018, The role of complement in synaptic pruning and neurodegeneration (2018)
presumey2022, Complement system in schizophrenia: where we are and where we need to go (2022)
sarlus2022, Microglia in Alzheimer's disease (2022)
sekar2016, Schizophrenia risk from complex variation of complement component 4 (2016) [1](https://doi.org/10.1038/nature16549)
shi2020, Complement C3-deficient mice do not develop age-related retinal degeneration (2020)
steckham2019, The emerging role of complement in neurodegeneration (2019)
van2020, Opposing roles of C4A and C4B in multiple sclerosis: implications for neurodegeneration (2020)
veenvliet2020, Cross-talk between neuroinflammation and neurodegeneration in Alzheimer's disease: the role of complement C4 (2020)
wu2019, C4 in brain: implications for understanding synaptic remodeling and schizophrenia (2019) [1](https://doi.org/10.1007/s11064-019-02852-w)
zhou2020, Complement component 4 is increased in Alzheimer's disease brains (2020) [1](https://doi.org/10.1007/s12035-020-02013-1)
Pathway Diagram
The following diagram shows the key molecular relationships involving C4A Gene discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-c4a |
| kg_node_id | C4A |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-02c311580719 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-c4a'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-c4a?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[C4A Gene](http://scidex.ai/artifact/wiki-genes-c4a)
http://scidex.ai/artifact/wiki-genes-c4a